Last updated: November 5, 2026
Praziquantel is a mature, off-patent anthelmintic with global demand driven by schistosomiasis control, foodborne trematode treatment, veterinary use and periodic public-health procurement. Its core molecule has no meaningful remaining exclusivity barrier in major markets. Commercial growth is therefore volume-led rather than price-led.
The strongest near-term growth driver is expanded mass drug administration in Africa. The most commercially differentiated opportunity is pediatric reformulation, particularly an easier-to-administer 150 mg dispersible tablet for young children. Revenue visibility remains limited because the largest human-use program is supplied through donations and public procurement rather than a conventional branded pharmaceutical model.
What is praziquantel and where is it used?
Praziquantel is a broad-spectrum antiparasitic medicine used against schistosomes and several cestode and trematode infections. It is included on the World Health Organization Model List of Essential Medicines and is the principal medicine used for schistosomiasis treatment [1].
Principal indications
| Use |
Primary patient group |
Commercial structure |
| Schistosomiasis |
Children and adults in endemic regions |
Government procurement, donor supply and mass drug administration |
| Taeniasis |
Humans with tapeworm infection |
Retail, hospital and public-sector treatment |
| Clonorchiasis and opisthorchiasis |
Humans with foodborne fluke infections |
Hospital and retail treatment |
| Veterinary helminth infections |
Dogs, cats, livestock and aquaculture species |
Branded and generic animal-health products |
| Preventive campaigns |
School-age children and at-risk populations |
Donor-funded or government-funded distribution |
Praziquantel is usually administered as tablets. Its bitter taste, large tablet size and need for weight-based dosing complicate treatment in young children. Those attributes create the main product-development opportunity in an otherwise commoditized market.
How large is the praziquantel market?
No major manufacturer reports praziquantel revenue as a standalone financial line. The market must be assessed through treatment volumes, procurement channels and branded-product sales.
The human market has two distinct segments:
- A high-volume, low-price public-health segment dominated by schistosomiasis programs.
- A smaller commercial segment comprising prescriptions, pharmacies, hospitals, travel-related treatment and veterinary products.
WHO estimates that hundreds of millions of people require preventive chemotherapy for schistosomiasis, while treatment coverage remains below the level required to eliminate transmission in many endemic countries [1]. This creates structural demand for tablets even when unit prices remain low.
Market economics by segment
| Segment |
Demand outlook |
Pricing power |
Margin profile |
| African mass drug administration |
High volume |
Low |
Low to moderate |
| Hospital and pharmacy prescriptions |
Stable |
Moderate |
Moderate |
| Veterinary products |
Stable to growing |
Higher |
Moderate to high |
| Pediatric dispersible formulation |
Potentially high |
Higher than standard tablets |
Dependent on procurement |
| API supply |
Volume-dependent |
Low |
Commodity-like |
Public-health demand is more predictable than commercial demand, but it produces weaker economics. Large tenders and donations suppress average selling prices. Veterinary products can generate better margins because manufacturers control branding, packaging, species-specific dosing and distribution.
When does praziquantel lose exclusivity?
Praziquantel lost practical market exclusivity decades ago. The compound was developed in the 1970s and entered human use in the early 1980s. Core composition-of-matter protection has expired in the United States, Europe and other major pharmaceutical markets.
Exclusivity position
| Protection category |
Current position |
| Original compound patent |
Expired |
| Original human-use product protection |
Expired |
| Regulatory exclusivity |
Expired |
| Generic entry |
Legally available in principle |
| Core API barriers |
Manufacturing know-how and regulatory compliance, not patent exclusivity |
| New pediatric formulations |
Potentially patentable or otherwise protectable |
| New salts, eutomer products or delivery systems |
Potential secondary protection |
The practical consequence is that a competitor does not need to license the original praziquantel invention to manufacture a standard tablet. Entry depends on pharmaceutical quality, registration, bioequivalence where applicable, supply reliability and access to procurement channels.
What is the FDA and Orange Book status of praziquantel?
The U.S. Food and Drug Administration approved Biltricide, the Bayer product, for human treatment of several parasitic infections. The product is associated with NDA 018714 in FDA records [2].
The U.S. product is a prescription tablet. Its commercial position is based on brand recognition and regulatory history rather than active compound exclusivity.
Orange Book implications
The relevant Orange Book conclusions are:
- Praziquantel has no active composition patent that blocks generic manufacture.
- Any historic Biltricide patent listings do not create a current commercial barrier equivalent to an active pharmaceutical patent.
- A generic entrant would face FDA approval, manufacturing and quality requirements rather than a material patent cliff.
- New pediatric products may have separate regulatory and patent positions that do not apply to standard praziquantel tablets.
The absence of meaningful core exclusivity makes an Abbreviated New Drug Application strategy theoretically viable. Actual entry economics depend on the addressable U.S. market, reference-product supply, bioequivalence requirements and the ability to obtain a commercially sustainable price.
What patents protect praziquantel formulations?
Standard praziquantel tablets are not protected by a current, commercially significant core patent estate. The main patent opportunity is in differentiated formulations.
Potentially protectable technologies
Pediatric dispersible tablets
The Pediatric Praziquantel Consortium has developed a 150 mg tablet intended for children between approximately three and six years of age. The formulation addresses swallowing difficulty, dosing flexibility and palatability limitations associated with conventional tablets [3].
Possible protection may cover:
- Tablet composition
- Taste-masking systems
- Disintegration characteristics
- Particle size or solid-state form
- Manufacturing process
- Pediatric dosing regimens
- Use in children below the conventional tablet age range
L-praziquantel and eutomer products
Praziquantel is a racemate. The L-enantiomer is the more pharmacologically active component, while the D-enantiomer contributes to bitterness and may have limited therapeutic value. A product based on L-praziquantel could support new patents or regulatory differentiation if it demonstrates improved palatability, tolerability, dosing or pediatric performance.
Veterinary formulations
Veterinary products may use species-specific tablets, oral pastes, spot-on combinations or injectable products. Protection may attach to the delivery system, combination therapy, dosing protocol or manufacturing process rather than to praziquantel itself.
What is the pediatric praziquantel opportunity?
Pediatric reformulation is the clearest product-development opportunity in the praziquantel market.
Standard tablets create four operational problems:
- Young children may be unable to swallow them.
- Weight-based dosing can require tablet splitting.
- Bitter taste reduces acceptance.
- School-based programs need rapid, reliable administration.
The Pediatric Praziquantel Consortium includes pharmaceutical, academic and public-health partners working toward a child-appropriate formulation. Merck KGaA has played a central role in the consortium and in the supply of praziquantel for schistosomiasis programs [3, 4].
Commercial assessment
A pediatric product could command a higher price than a standard tablet if it receives public-health adoption and donor or government financing. Its market value will depend on:
- WHO policy adoption
- Regulatory approval in endemic countries
- Procurement eligibility
- Donor funding
- Production scale
- Stability in hot and humid climates
- Manufacturing cost
- Whether the product replaces or supplements donated standard tablets
The pediatric product is unlikely to displace the entire conventional market. Older children and adults will continue to use standard tablets, while young-child treatment could become a separate procurement category.
How does the global donation model affect praziquantel revenue?
Merck KGaA has supplied praziquantel for schistosomiasis control through a long-running donation program coordinated with WHO. The company has donated more than one billion tablets over the life of the program, according to public company and WHO materials [4, 5].
This model has three financial effects:
- It increases total treatment volume.
- It reduces the revenue available from the poorest endemic-country segment.
- It gives the principal donor a large role in product specifications, supply planning and program design.
Donation volumes can represent a substantial share of global human-use demand. They should not be treated as equivalent to commercial sales. The donated supply creates public-health reach but does not produce ordinary product revenue for the manufacturer.
For investors, the distinction is material. A rise in tablets distributed can coexist with flat or declining pharmaceutical revenue if incremental volume is donated or tender-priced.
What companies manufacture or sell praziquantel?
The market includes originator-linked suppliers, generic pharmaceutical manufacturers, animal-health companies and API producers.
Key commercial participants
| Company or group |
Role |
| Merck KGaA |
Major donor and supplier for human schistosomiasis programs; associated with Cesol and consortium activity |
| Bayer |
Historical U.S. Biltricide sponsor and branded human-use supplier |
| Generic manufacturers |
Human tablets, APIs and regional products |
| Veterinary manufacturers |
Companion-animal and livestock products |
| Pediatric Praziquantel Consortium |
Development and regulatory coordination for child-appropriate formulation |
The competitive landscape is fragmented outside donor-supported programs. Local registration and procurement eligibility matter more than global brand strength in many endemic markets.
Which companies are challenging praziquantel exclusivity?
No major Paragraph IV challenge is central to current praziquantel market dynamics because the original product is already off patent. Competition comes through ordinary generic development, local registrations and tender participation.
Paragraph IV assessment
A Paragraph IV filing is unlikely to be the defining route for standard praziquantel entry because:
- Core patents have expired.
- The reference product is old.
- The main market is outside the U.S.
- Human demand is concentrated in public-health procurement.
- Commercial barriers are primarily regulatory and economic.
A Paragraph IV dispute could arise around a later-listed formulation, method-of-use patent or pediatric product, but that would concern the secondary product rather than praziquantel as a molecule.
What patent litigation affects praziquantel?
No major active U.S. patent litigation currently defines standard praziquantel access. Litigation risk is more likely to arise around:
- New pediatric formulations
- L-praziquantel products
- Combination products
- Veterinary delivery systems
- Regulatory exclusivity attached to a newly approved formulation
- Manufacturing or supply agreements
The absence of major molecule-level litigation supports a low legal barrier to generic standard tablets. It does not eliminate dispute risk for differentiated products.
How strong is the praziquantel patent estate?
The core praziquantel patent estate is weak because the foundational patents have expired. The secondary estate is potentially stronger but commercially unproven.
| Patent layer |
Strength |
Commercial relevance |
| Core molecule |
Low |
Minimal exclusivity |
| Standard tablet |
Low |
Generic competition |
| Pediatric dispersible tablet |
Moderate, depending on claims and approval |
High public-health relevance |
| L-praziquantel |
Moderate to potentially high |
Depends on clinical and regulatory differentiation |
| Veterinary delivery systems |
Moderate |
Relevant in branded animal health |
| Manufacturing processes |
Variable |
Can create practical barriers if difficult to replicate |
A formulation patent is valuable only if it protects a product that procurement agencies, physicians or animal-health customers will adopt. Broad claims covering routine tablet manufacture are vulnerable to validity and design-around challenges. Narrow claims tied to a validated pediatric formulation may provide stronger practical protection.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are more important than patent barriers for conventional praziquantel.
Key operational barriers
- Reliable API sourcing
- Control of impurities and polymorphic form
- Consistent tablet weight and content uniformity
- Taste masking
- Stability under tropical conditions
- Large-volume production capacity
- Registration in multiple African jurisdictions
- Qualification for WHO-linked procurement
- Compliance with current good manufacturing practices
- Tender pricing at sustainable margins
Praziquantel API production is chemically established, but large-scale supply for mass treatment requires dependable capacity and quality systems. A manufacturer that wins a large tender must avoid stockouts, maintain batch consistency and meet compressed delivery schedules.
How does praziquantel compare with competing antiparasitic drugs?
Praziquantel has a stronger position in schistosomiasis than most alternatives.
| Drug |
Main target |
Position versus praziquantel |
| Praziquantel |
Schistosomiasis, cestodes and trematodes |
Standard treatment for schistosomiasis |
| Oxamniquine |
Schistosoma mansoni |
Narrower species coverage and less central to current programs |
| Metrifonate |
Schistosoma haematobium |
Limited use and less convenient dosing |
| Triclabendazole |
Fasciola hepatica and related flukes |
Important for fascioliasis, not a broad replacement for praziquantel |
| Albendazole |
Soil-transmitted helminths |
Complements rather than replaces praziquantel |
| Niclosamide |
Tapeworms |
Narrower use and not a schistosomiasis substitute |
Praziquantel benefits from established guidelines, long clinical experience, broad parasite coverage and large-scale program infrastructure.
What is the financial trajectory for praziquantel?
The financial trajectory is best described as stable-volume, low-price human demand with selective upside from pediatric and veterinary products.
Base-case trajectory
The base case includes:
- Continued high-volume public-health procurement
- Ongoing Merck-linked donations
- Limited price increases in endemic-country tenders
- Continued generic competition
- Stable branded U.S. and European prescription demand
- Gradual expansion of pediatric treatment once an appropriate formulation is approved and procured
Upside case
The upside case depends on:
- Faster expansion of schistosomiasis treatment coverage
- Adoption of a pediatric dispersible product
- New donor commitments
- Higher veterinary demand
- Successful L-praziquantel commercialization
- Increased treatment of foodborne trematode infections
Downside case
The downside case includes:
- Donor funding constraints
- Procurement delays
- Local manufacturing interruptions
- Weak adoption of a premium pediatric product
- Price compression from additional generic suppliers
- Reduced branded sales as low-cost alternatives gain registration
Revenue exposure by business model
| Business model |
Revenue outlook |
| Originator-style human brand |
Mature and limited |
| Generic human tablets |
Volume opportunity, low margins |
| Donor supply |
High volume, limited reported revenue |
| Pediatric product |
Potentially higher unit economics, dependent on public procurement |
| Veterinary branded products |
Best pricing and margin potential |
| API manufacturing |
Scale-dependent and exposed to price competition |
There is no defensible basis for assigning a standalone global revenue figure to praziquantel from public company filings. The more reliable commercial metric is treatment volume, especially the number of tablets procured for mass drug administration.
What generic launch risks exist for praziquantel?
A generic launch is legally feasible but commercially uneven.
United States
The U.S. opportunity is constrained by the size of the prescription market and the presence of established branded supply. A generic entrant would need FDA approval and a viable commercial strategy. Price erosion could be rapid if several suppliers enter.
Africa
Africa offers the largest volume opportunity, particularly in schistosomiasis programs. The barriers are tender qualification, donor procurement rules, country-specific registration, working capital and supply reliability.
Latin America and Asia
These regions have demand for schistosomiasis and foodborne trematode treatment, but volumes vary sharply by country. Local epidemiology and public reimbursement determine commercial attractiveness.
Veterinary markets
Veterinary entry can be more attractive because products are sold through commercial distribution and often combined with other antiparasitic agents. Competition remains intense, particularly in companion-animal products.
What is the geographic coverage of praziquantel protection?
The original molecule is effectively unencumbered by active patent protection in major markets. Geographic differences now arise from:
- National product registrations
- Local formulation patents
- Regulatory exclusivity for new products
- Procurement rules
- Manufacturing licenses
- Data-protection regimes
- Donor purchasing requirements
A new pediatric formulation could have different protection profiles in the United States, Europe, China, India and African jurisdictions. Patent term, examination standards and national filing strategies will determine the practical scope.
Key Takeaways
- Praziquantel is a mature, off-patent antiparasitic with no meaningful core-molecule exclusivity.
- Schistosomiasis mass drug administration is the primary volume driver.
- Merck KGaA’s donation program supports global treatment scale but limits direct revenue capture.
- Standard human tablets are exposed to generic competition and price pressure.
- Pediatric dispersible tablets and L-praziquantel are the main differentiated-product opportunities.
- Veterinary products offer better commercial pricing than donor-funded human treatment.
- Paragraph IV litigation is not central to standard praziquantel entry.
- Manufacturing quality, tender access and supply reliability matter more than legacy patents.
- No public company provides a reliable standalone praziquantel revenue figure.
- Financial growth is likely to come from higher treatment volumes, pediatric adoption and veterinary products rather than molecule-level price increases.
FAQs
Is praziquantel still patented?
The original praziquantel compound and conventional tablet products are off patent. New pediatric, enantiomeric, combination or delivery-system products may have separate patent protection.
Is Biltricide protected from generic competition?
Biltricide is not protected by meaningful active molecule-level exclusivity. A generic competitor would primarily face FDA approval, manufacturing and commercial-market barriers.
Who donates praziquantel for schistosomiasis?
Merck KGaA has been the principal corporate donor associated with large-scale praziquantel supply for schistosomiasis programs, working with WHO and endemic-country partners.
Does praziquantel have biosimilar risk?
No. Praziquantel is a chemically synthesized small molecule, not a biologic. The relevant competitive risk is generic substitution, not biosimilar competition.
Is pediatric praziquantel commercially attractive?
It can be commercially attractive if the product receives regulatory approval, WHO or donor procurement support and sufficient volume. Its value rests on improved administration and public-health adoption rather than broad molecule exclusivity.
References
- World Health Organization. (2024). Schistosomiasis. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
- U.S. Food and Drug Administration. (n.d.). Biltricide prescribing information and Drugs@FDA records. https://www.accessdata.fda.gov/scripts/cder/daf/
- Pediatric Praziquantel Consortium. (n.d.). Development of a child-friendly praziquantel formulation. https://www.pediatricpraziquantelconsortium.org/
- Merck KGaA. (2023). Merck extends praziquantel donation commitment for schistosomiasis control. https://www.merckgroup.com/
- World Health Organization. (2023). WHO and Merck extend partnership to eliminate schistosomiasis as a public health problem. https://www.who.int/ end:VEVENT
